Clinical Phase 1b/2 Study Results for Safety, Pharmacokinetics, and Efficacy of ND-L02-s0201, a Novel Targeted Lipid Nanoparticle (LNP) Delivering HSP47 siRNA for the Treatment of Patients with Advanced Liver Fibrosis

导出原文传递

翻译打印收藏纠错

作者： Lawitz, Eric ^[1] ; Balabanska, Rozalina I. ^[2] ; Charles, Edgar D. ^[3] ; Friedman, Scott L. ^[4] ; Gutierrez, Julio A. ^[5] ; Niitsu, Yoshiro ^[6] ; Poordad, Fred ^[7] ; Sanyal, Arun J. ^[8] ; Tanaka, Yasunobu ^[9] ; Thienel, Ulrich ; Ying, Wenbin ; Maruyama, Kageshi

作者单位： Icahn Sch Med Mt Sinai, New York, NY 10029 USA ^[1] Bristol Myers Squibb, Princeton, NJ USA ^[2] Sapporo Med Univ, Sapporo, Hokkaido, Japan ^[3] Nitto Denko Corp, Tokyo, Japan ^[4] RRD Int, Rockville, MD USA ^[5] Texas Liver Inst, San Antonio, TX USA ^[6] Virginia Commonwealth Univ, Richmond, VA USA ^[7] Tokuda Hosp Sofia, Sofia, Bulgaria ^[8] Nitto BioPharma Inc, San Diego, CA USA ^[9]

发布时间 2020-08-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Hepatology

2017年66卷Suppl.1期

237A-237A页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Clinical Phase 1b/2 Study Results for Safety, Pharmacokinetics, and Efficacy of ND-L02-s0201, a Novel Targeted Lipid Nanoparticle (LNP) Delivering HSP47 siRNA for the Treatment of Patients with Advanced Liver Fibrosis

Hepatology

相似文献

Hepatology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Clinical Phase 1b/2 Study Results for Safety, Pharmacokinetics, and Efficacy of ND-L02-s0201, a Novel Targeted Lipid Nanoparticle (LNP) Delivering HSP47 siRNA for the Treatment of Patients with Advanced Liver Fibrosis

Hepatology

相似文献

Hepatology

相关期刊

检索历史清除